Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with IA vs Standard Chemotherapy in Untreated AML
NCT01802333Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2013
- Primary completion
- Jun 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of vorinostat in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Feb 2013; status: completed.
02
Drugs
vorinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01802333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802333.